Claritas Pharmaceuticals, Inc. (TSXV:CLAS)

Healthcare

Claritas Pharmaceuticals Inc is a specialized healthcare care company that uses biotechnology to develop treatment for unmet medical conditions.

The clinical stage firm is domiciled in San Francisco, California. It is listed on junior trading platform listed on TSX Venture where its common stocks trade under ‘CLAS’.

The biopharma firm, formerly known as Kalytera Therapeutics, Inc, rebranded itself in April 2021. It is also listed OTC Market under ‘KALTF’ symbol.

Claritas Pharmaceuticals Inc discovers, research, develop, manufactures, and commercializes pharmaceutical products and therapies for several diseases and disorders.

Some of the product offerings are in development stage.

CLA-1816 is a potent, non-psychotropic, non-toxic oral analgesic, unlike opioid analgesics that enables the alpha3 glycine receptor in the spine to stop sending a pain signal to the brain.

R-107 is a patented technology in 40 countries, including the United States, South Korea, Japan, Australia, Brazil, Russia, China, Europe, and India. Through its R-107, the firm aims to develop anti-viral therapy to naturally release nitric oxide to counter the COVID-19 and other viral infections.

The product pipeline is called R-107 and Vaccines.

Claritas Pharmaceutical Inc strategically collaborates with Salzman Group, Ltd and other organizations to speed up the development phase of R-107 and finish its clinical studies to treat COVID-19.

In a press release dated April 8, 2021, Claritas Pharmaceutical Inc announced to expand the R-107 development program for COVID-19 viral sepsis solutions that it claims to be the primary cause of patient’s death.

Furthermore, in April 2021, the biopharmaceutical firm for the Phase I clinical study of R-107 entered into a pact with CMAX Clinical Research Pty Ltd. The CA-based bio-pharma company holds a total area of approximately 8,500 square feet on a lease, including laboratories, office, and archival space. The property is fully serviced with the requirements to undergo analytical, bioanalytic and synthetic chemical work, the biopharma firm claims.